Abbott Labs (ABT) Issues Encouraging Update for ABSORB II
Tweet Send to a Friend
Abbott Labs (NYSE: ABT) announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE